A venture philanthropy fund based in the Western US makes equity investments of varied amounts; significant previous investments have ranged from $1-5 million. The fund invests globally, and will make between 2-3 allocations in the next 6-9 months.

The venture philanthropy group invests primarily in therapeutics to treat a specific orphan disease. However, the fund is open to exploring any therapeutic technology, and has recently invested in small molecule drugs. The fund considers projects are at a range of development stages, from preclinical/drug discovery to Phase II trials for repurposed drugs.

The fund looks for experienced researchers with prior records of success, and projects from both public and private companies are considered.

A venture capital firm founded in 2000 and based out in the Eastern US manages four funds with a combined $250 million in assets under management. The firm’s most recent fund closed at over $100 million, with up to 20% of the committed capital going to seed and early stage companies and projects.

The firm typically invests between $2 and $4 million initially, and up to $10 million over the lifetime of the investment. Investments are generally in the form of milestone-based equity tranches. However, the firm also has experience in working with convertible notes. They are looking to make 4-6 allocations in the next 6-9 months.

The VC is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Technology and HealthCare IT spaces. In the Therapeutics space the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases.

For companies developing therapeutics, the firm is looking for companies primarily with a lead product in preclinical trials, although they will consider companies with products having recently entered Phase I. The firm also has generally stayed away from – and is not currently seeking – companies working with Regenerative Medicine and Wound Care. In the Medical Technology space, the firm strongly prefers that the company have at least have an early prototype of their product and the firm is opportunistic in terms of device subsector.

An angel group that began making investments into life sciences in 2000 and is based in the Eastern US, and manages a fund structure and has raised four funds to date. The firm looks to invest along with other members in its network to companies that are looking to raise $1-$3 million in capital. The firm plans to make 6 allocations in the next 6-9 months.

The group is currently looking for companies in the Healthcare IT and Medical device spaces. The firm is agnostic in terms of indication, but they are not interested in companies whose products will require an arduous FDA approval process. The firm is interested in companies who already have a prototype of their product available.

The group is only interested in companies with experienced management and looks to be an activist investor. The firm will not consider companies whose are going to require more than $ 10 million in total investment over their life time. The firm is looking for highly capital efficient companies that have a clear plan to partner or get bought out by a larger organization.

A private equity advisory firm based in Europe that primarily caters to the investment interest of family offices has a large investment range, and has made allocations in the past from a few hundred thousand dollars into the 10’s of millions. The firm makes equity investments into privately held firms and is looking to invest $20 – $80 million across 4 investments in the next 6-9 months. The firm has no geographical preference.

This particular firm is looking for companies in the Biotech Therapeutics and Diagnostics, Medtech, and R&D Services Sectors and is opportunistic in terms of subsector and indication.

The advisory firm is only interested in companies that are generating revenue and have been approved for reimbursement. As such they will only invest into firms that have a product on the market though they are open to firms across all ranges of EBITDA and Market Cap.

A crowdfunding platform for high-impact life science startups based in the Eastern US also makes  angel investments in life science companies, typically of $60,000-$100,000 in equity provided at the seed stage. The platform supports startups globally, and seeks angel opportunities throughout the USA.

Within the life science space, the platform focuses on therapeutic drugs, but is also interested in medical technology. Therapeutic investments are provided to companies with drugs at the Phase I or Phase II stages of development; they do not invest in products that are still at the preclinical stage.

They prefer to invest in companies that have a CEO, founder or co-owner who is an MD, but otherwise have no specific requirements for managers or researchers.  As investments are made at the seed stage, public companies are not eligible.

A biotech-focused Hedge Fund based in the Western US currently manages nearly $1b in assets under an evergreen fund structure, and is currently looking for investment opportunities across the United States and Europe. They have no set mandate for the number of companies they plan to allocate to over the next 6-9 months, and their investment size varies by case.

The fund is currently only looking for companies developing therapeutics, and is agnostic in terms of therapeutic area and target. They prefer to invest in companies with assets in later stages of clinical trials – typically in Phases II and III.

Fundamentally driven, they have a strong preference for companies that have gone public or are considering going public in the near future. Although the firm does prefer later stage companies, they do not require that the company is currently generating revenue. In terms of management team, the fund is looking for experienced management to be in place. However, they do not require that the current management be the long-term team for the company.

A venture capital firm that has two offices in the Eastern US has approximately $40 million in total assets under management, and is seeking to make equity investments in 2-3 companies in the next 6 to 9 months. The average first investment in a company is between $0.1 million to $ 0.75 million, though it can invest up to $ 1.5 million, depending on the opportunity. They prefer to invest in seed and early-stage companies located in the Southeast and Mid-Atlantic regions of the US with a focus in the states of North Carolina and Florida.

This particular VC is currently looking for new investment opportunities in Medical Technology and Healthcare IT spaces, specifically in companies producing medical devices and software. The firm is very opportunistic in terms of medical devices, and it would consider companies operating within any subsector of medical technology. They generally make investments in pre-clinical and prototype stages within medical technology sector.

This fund will consider pre-revenue companies and make initial investments in companies with no revenues. They prefer to invest in technologies that are disruptive to existing markets or enable entirely new ones. The firm will not consider any biotechnology and pharmaceutical companies, and additionally would not be interested in growth companies.